Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices.

A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...

Thus, the incentive for income investors to buy Pfizer stock is high. But others will argue that so too is the risk. And ...

Wednesday, May 13, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta ...

Pfizer has won expanded European Commission approval of its Hympavzi hemophilia drug for two patient populations. Pfizer on Wednesday said the green light covers patients ages 12 and older weighing at ...

Pfizer's new and recently acquired products generated 22% operational growth in Q1. The company faces a challenging road ...

Hantavirus pulmonary infection is a disease caused by some hantaviruses, not the Pfizer-BioNTech COVID-19 vaccine, contrary ...

Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.